It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
RMD’s FA Score shows that 1 FA rating(s) are green whileSYK’s FA Score has 1 green FA rating(s).
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
RMD’s TA Score shows that 4 TA indicator(s) are bullish while SYK’s TA Score has 6 bullish TA indicator(s).
RMD (@Pharmaceuticals: Other) experienced а -4.49% price change this week, while SYK (@Medical/Nursing Services) price change was +1.26% for the same time period.
The average weekly price growth across all stocks in the @Pharmaceuticals: Other industry was +3.91%. For the same industry, the average monthly price growth was +4.90%, and the average quarterly price growth was +15.22%.
The average weekly price growth across all stocks in the @Medical/Nursing Services industry was +2.89%. For the same industry, the average monthly price growth was +5.50%, and the average quarterly price growth was +9.92%.
RMD is expected to report earnings on Oct 23, 2025.
SYK is expected to report earnings on Oct 30, 2025.
Pharmaceuticals (Other) comprise companies that are involved in the discovery, development or manufacturing of therapeutic and preventative medicines. They often collaborate with or acquire other pharmaceutical/healthcare firms. Examples of companies in this segment include Bausch Health Companies Inc., Icon Plc and Perrigo Company Plc.
@Medical/Nursing Services (+2.89% weekly)The medical/nursing services includes companies that provide medical-related services such as ambulance services, dialysis centers, respiratory therapy, blood testing and rehabilitation services. DaVita Inc., Chemed Corporation and Guardant Health, Inc. are examples of companies in this industry.
RMD | SYK | RMD / SYK | |
Capitalization | 40.3B | 149B | 27% |
EBITDA | 1.92B | 5.76B | 33% |
Gain YTD | 21.201 | 8.709 | 243% |
P/E Ratio | 28.96 | 51.61 | 56% |
Revenue | 5.15B | 23.8B | 22% |
Total Cash | 1.21B | 2.46B | 49% |
Total Debt | 852M | 16.6B | 5% |
RMD | SYK | ||
---|---|---|---|
OUTLOOK RATING 1..100 | 57 | 63 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 38 Fair valued | 70 Overvalued | |
PROFIT vs RISK RATING 1..100 | 64 | 16 | |
SMR RATING 1..100 | 100 | 100 | |
PRICE GROWTH RATING 1..100 | 21 | 55 | |
P/E GROWTH RATING 1..100 | 100 | 100 | |
SEASONALITY SCORE 1..100 | 75 | n/a |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
RMD's Valuation (38) in the Medical Specialties industry is in the same range as SYK (70). This means that RMD’s stock grew similarly to SYK’s over the last 12 months.
SYK's Profit vs Risk Rating (16) in the Medical Specialties industry is somewhat better than the same rating for RMD (64). This means that SYK’s stock grew somewhat faster than RMD’s over the last 12 months.
SYK's SMR Rating (100) in the Medical Specialties industry is in the same range as RMD (100). This means that SYK’s stock grew similarly to RMD’s over the last 12 months.
RMD's Price Growth Rating (21) in the Medical Specialties industry is somewhat better than the same rating for SYK (55). This means that RMD’s stock grew somewhat faster than SYK’s over the last 12 months.
RMD's P/E Growth Rating (100) in the Medical Specialties industry is in the same range as SYK (100). This means that RMD’s stock grew similarly to SYK’s over the last 12 months.
RMD | SYK | |
---|---|---|
RSI ODDS (%) | 1 day ago56% | N/A |
Stochastic ODDS (%) | 1 day ago73% | 1 day ago48% |
Momentum ODDS (%) | 1 day ago52% | 1 day ago61% |
MACD ODDS (%) | 1 day ago61% | 1 day ago67% |
TrendWeek ODDS (%) | 1 day ago56% | 1 day ago56% |
TrendMonth ODDS (%) | 1 day ago52% | 1 day ago46% |
Advances ODDS (%) | 11 days ago63% | 9 days ago56% |
Declines ODDS (%) | 1 day ago57% | 1 day ago51% |
BollingerBands ODDS (%) | 1 day ago73% | 1 day ago60% |
Aroon ODDS (%) | 1 day ago65% | 1 day ago60% |
1 Day | |||
---|---|---|---|
ETFs / NAME | Price $ | Chg $ | Chg % |
DWAS | 90.26 | 0.34 | +0.38% |
Invesco Dorsey Wright SmallCap Momt ETF | |||
BSMU | 21.65 | 0.01 | +0.02% |
Invesco BulletShares 2030 Muncpl Bd ETF | |||
STIP | 103.84 | N/A | N/A |
iShares 0-5 Year TIPS Bond ETF | |||
MCDS | 57.75 | N/A | N/A |
JPMorgan Fundamental Data Sci Md Cor ETF | |||
THTA | 15.01 | -0.01 | -0.06% |
SoFi Enhanced Yield ETF |
A.I.dvisor indicates that over the last year, RMD has been loosely correlated with SOLV. These tickers have moved in lockstep 46% of the time. This A.I.-generated data suggests there is some statistical probability that if RMD jumps, then SOLV could also see price increases.
Ticker / NAME | Correlation To RMD | 1D Price Change % | ||
---|---|---|---|---|
RMD | 100% | -2.33% | ||
SOLV - RMD | 46% Loosely correlated | -0.32% | ||
RVTY - RMD | 40% Loosely correlated | +0.72% | ||
SYK - RMD | 39% Loosely correlated | -0.89% | ||
IDXX - RMD | 39% Loosely correlated | +0.96% | ||
MTD - RMD | 38% Loosely correlated | -0.17% | ||
More |
A.I.dvisor indicates that over the last year, SYK has been loosely correlated with BSX. These tickers have moved in lockstep 66% of the time. This A.I.-generated data suggests there is some statistical probability that if SYK jumps, then BSX could also see price increases.